Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor
Sponsor: Fred Hutchinson Cancer Center
Listed as NCT03338972, this PHASE1 trial focuses on Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma and remains completed. Sponsored by Fred Hutchinson Cancer Center, it has been updated 20 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
20 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2023 — Nov 2023 [monthly]
Completed PHASE1
-
Sep 2022 — Oct 2023 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 15 earlier versions
-
May 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Status: Suspended → Recruiting
-
Apr 2020 — Jun 2020 [monthly]
Suspended PHASE1
Status: Recruiting → Suspended
-
Feb 2020 — Apr 2020 [monthly]
Recruiting PHASE1
-
Dec 2019 — Feb 2020 [monthly]
Recruiting PHASE1
-
Jun 2019 — Dec 2019 [monthly]
Recruiting PHASE1
-
Apr 2019 — Jun 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE1
-
Dec 2017 — Mar 2018 [monthly]
Recruiting PHASE1
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fred Hutchinson Cancer Center
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .